New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
14:42 EDTALNY, NVS, TKMR, ARWRAlnylam slips after Novartis reportedly cuts back RNAi development
Shares of Alnylam (ALNY) are lower in afternoon trading after a biotech focused newsletter reported that its partner, pharmaceutical giant Novartis (NVS), confirmed plans to "significantly reduce" its ribonucleic acid interface, or RNAi, research efforts. WHAT'S NEW: FierceBiotech reported earlier today that Novartis has decided to significantly cut back its once-ambitious RNAi research efforts, citing ongoing problems associated with delivering these therapies and the small number of relevant targets they could target. A total of 26 Novartis staffers were working full-time on the RNAi program full time, which grew out of a partnership with Alnylam, the report noted. OTHERS TO WATCH: Tekmira Pharmaceuticals (TKMR), like Alnylam, is focused on advancing ribonucleic acid interference therapeutics. Arrowhead Research (ARWR) is another biopharmaceutical company developing RNAi therapeutics. PRICE ACTION: In afternoon trading, Alnylam shares are down 4.5% to $52.58, Tekmira's stock is down nearly 16% to $15.49, and Arrowhead shares are off 3% to $12.71. Shares of Novartis are up about 1% to $83.48.
News For ALNY;NVS;TKMR;ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 15, 2014
08:58 EDTTKMRTekmira volatility up, 2nd Texas health-care worker tests positive for Ebola
Subscribe for More Information
06:06 EDTARWRArrowhead pullback since ARC-520 data an overreaction, says Piper Jaffray
Subscribe for More Information
October 14, 2014
14:54 EDTARWRQVT Financial raises passive stake in Arrowhead to 7.62% from 5.29%
Subscribe for More Information
11:23 EDTNVSBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTTKMRNIH says several potential Ebola treatments under development
Subscribe for More Information
10:10 EDTTKMRNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
09:04 EDTTKMRChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
08:04 EDTALNYAlnylam presents new ALN-TTRsc Phase 1 trial data
Subscribe for More Information
05:40 EDTALNY, TKMRTekmira partner Alnylam reports positive clinical data for Patisiran study
Tekmira Pharmaceuticals (TKMR) reported that Alnylam Pharmaceuticals (ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension, or OLE, study in patients with Familial Amyloidotic Polyneuropathy, or FAP. Patisiran is an RNAi therapeutic targeting transthyretin, or TTR, in development for the treatment of TTR-mediated amyloidosis, or ATTR, which is enabled by Tekmira's lipid nanoparticle, or LNP, technology. Alnylam presented data at the American Neurological Association's 2014 Annual Meeting. Results showed a mean 0.95 point decrease in modified Neuropathy Impairment Score at six months in 19 patients with mNIS+7 data available for the current analysis. This decrease in neuropathy progression compares favorably with the 7 to 10 point increase in mNIS+7 at six months that can be estimated from historical data sets in untreated FAP patients with similar baseline characteristics.
October 13, 2014
16:28 EDTALNYOn The Fly: Closing Wrap
Stocks on Wall Street spent most of today's quiet session see-sawing across the flat-line before dropping sharply in the final hour of trading and closing at their lows. The market opened in negative territory but soon made a move to the upside and appeared ready to break the recent market slide that has seen the S&P lose about 5% of its value. Before the averages gained significant steam, they reversed again and moved back into negative ground. The averages moved in a fairly narrow range for most of the afternoon, before accelerating to the downside with conviction in the final hour of trading. ECONOMIC EVENTS: In the U.S., no economic data of note was reported and banks and bond markets were closed in observance of the Columbus Day holiday. In China, the nation's customs administration reported a trade surplus of about $31B for September. Exports in the month increased 15.3% from a year earlier, beating expectations and making for the biggest monthly increase since February 2013. Imports rose 7%, significantly outpacing the consensus projection for a 2% decline. COMPANY NEWS: The Wall Street Journal reported that CSX (CSX) was approached by a larger rival, Canadian Pacific (CP), about a possible merger. However, Credit Suisse analyst Allison Landry wrote in a note to investors that a merger between the two would not be able to occur, due to high regulatory hurdles. Still, CSX rose $1.76, or 5.88%, to $31.70 following the Journal's report, while Canadian Pacific fell $4.40, or 2.32%, to $184.97... Shares of Fiat Chrysler Automobiles (FCAU) made their debut on the New York Stock Exchange and opened at $9 per share. The stock of the newly merged company closed trading down about 1% at $8.92... J.C. Penney (JCP) selected Marvin Ellison, who is currently executive vice president of stores at Home Depot (HD), to become its next CEO. The stock, which was also downgraded to Sell from Neutral at UBS this morning, spent much of the trading day in positive ground but moved lower late in the session and closed down 3c, or 0.42%, at $7.09. MAJOR MOVERS: Among the notable gainers was Alnylam (ALNY), which advanced $13.83, or 18.98%, to $86.68 after the company announced data from study of its treatment for patients with familial amyloidotic polyneuropathy and Piper Jaffray raised its price target on the stock to $133 from $101 citing the trial results. Among the noteworthy losers was AutoNation (AN), which fell $4.11, or 8.01%, to $47.21 after another company in the same sector, Lithia Motors (LAD), lowered its profit outlook for the third and fourth quarter and issued a lower than expected earnings forecast for fiscal 2015. Shares of Lithia, meanwhile, plunged $16.85, or 20.84%, to $64.01. Also lower were shares of GoPro (GPRO), which fell $8.38, or 9.85%, to $76.67 after a French journalist reported that the son of racing legend Michael Schumacher attributed the severity of his father's brain injury following a skiing accident on the GoPro camera mounted to his helmet. INDEXES: The Dow fell 223.03, or 1.35%, to 16,321.07, the Nasdaq dropped 62.58, or 1.46%, to 4,213.66, and the S&P 500 declined 31.39, or 1.65%, to 1,874.74.
09:44 EDTALNYAlnylam price target raised to $133 on positive Ph. 2 results at Piper Jaffray
Piper Jaffray raised Alnylam's price target to $133 from $101 following positive Phase 2 open-label extension study with patisiran in patients with familial amyloidotic polyneuropathy.
07:33 EDTALNYAmerican Neurological Association to hold annual meeting
ANA 2014: 139th Annual Meeting is being held in Baltimore on October 12-14.
07:12 EDTTKMR, ALNY, ARWROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
07:11 EDTTKMRTekmira volatility elevated, Texas health-care worker tests positive for Ebola
Subscribe for More Information
06:44 EDTALNYAlnylam to host conference call
Subscribe for More Information
06:04 EDTALNYAlnylam's patisiran for polyneuropathy shows positive Phase 2 results
Subscribe for More Information
October 12, 2014
19:26 EDTTKMRPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTTKMRCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTTKMRNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTTKMRTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use